Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Revenue of Oragenics, Inc. (OGEN)
Revenue in 2023 (TTM): $37.65 K
According to Oragenics, Inc.'s latest financial reports the company's current revenue (TTM) is $37.65 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Oragenics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $37.65 K | $-15,452,951 | $-20,877,512 | $-20,655,737 | $-20,655,737 |
| 2022 | $131.52 K | $86.85 K | $-14,228,619 | $-14,288,389 | $-14,161,150 |
| 2021 | $86.99 K | $45.75 K | $-15,654,621 | $-15,711,614 | $-15,728,040 |
| 2020 | $ | $-51,705 | $-26,501,062 | $-26,430,699 | $-26,443,179 |
| 2019 | $ | $-62,622 | $-15,496,081 | $-15,566,003 | $-15,573,759 |
| 2018 | $ | $-30,110 | $-9,878,245 | $-9,914,141 | $-9,914,141 |
| 2017 | $ | $-65,803 | $-6,642,294 | $-6,731,525 | $-6,731,525 |
| 2016 | $ | $-75,044 | $-8,427,371 | $-8,497,316 | $-7,013,304 |
| 2015 | $1.18 M | $694.1 K | $-11,559,589 | $-11,711,333 | $-11,711,333 |
| 2014 | $939.93 K | $570.33 K | $-5,751,830 | $-5,789,519 | $-5,789,519 |
| 2013 | $1.03 M | $688.88 K | $-16,110,197 | $-16,068,754 | $-16,068,754 |
| 2012 | $1.33 M | $453.3 K | $-12,341,946 | $-13,090,446 | $-13,090,446 |
| 2011 | $1.44 M | $730.82 K | $-7,265,803 | $-7,678,868 | $-7,678,868 |
| 2010 | $1.31 M | $397.12 K | $-7,856,279 | $-8,538,602 | $-7,805,165 |
| 2009 | $641.29 K | $420.09 K | $-6,090,821 | $-5,519,348 | $-5,519,348 |
| 2008 | $233.54 K | $218.68 K | $-5,762,691 | $-6,021,742 | $-6,021,742 |
| 2007 | $133.09 K | $133.09 K | $-2,063,979 | $-2,311,712 | $-2,311,712 |
| 2006 | $66.18 K | $66.18 K | $-2,682,942 | $-2,935,719 | $-2,935,719 |
| 2005 | $ | $ | $-3,003,441 | $-3,251,378 | $-3,251,378 |
| 2004 | $196.21 K | $196.21 K | $-3,082,765 | $ | $-3,077,888 |
| 2003 | $ | $ | $-1,655,406 | $ | $-1,672,954 |